Condition: Multiple Myeloma · Sponsor: Bristol-Myers Squibb
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
This description comes directly from the study's public registry record.
BMS Study Connect Contact Center www.BMSStudyConnect.com · 855-907-3286 · Clinical.Trials@bms.com
First line of email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| UAB Comprehensive Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| John Theurer Cancer Center at Hackensack UMC | Hackensack, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Alberta Health Services AHS - Foothills Medical Centre FMC | Calgary, Alberta, Canada | Recruiting |
| University of Alberta - Cross Cancer Institute | Edmonton, Alberta, Canada | Recruiting |
| University Health Network UHN - Princess Margaret Hospital PMH | Toronto, Ontario, Canada | Recruiting |
| Oslo University Hospital | Oslo, Outside US and Canada, Norway | Recruiting |
| ICO - Hospital Germans Trias i Pujol | Barcelona, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
| Hospital Universitario Marques de Valdecilla | Santander, Spain | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05372354